{"prompt": "['Product: MK-3475', '57', 'Protocol/Amendment No.: 604-09', 'Instructions regarding supportive care needed with the chemotherapeutic agents administered', 'in this study can be found in the local product label for each agent. Infusion reactions and', 'injection site reactions will be managed by the investigator according to local product', 'labeling.', '5.7 Diet/Activity/Other Considerations', '5.7.1 Diet', 'Subjects should maintain a normal diet unless modifications are required to manage an AE', 'such as diarrhea, nausea, or vomiting.', '5.7.2 Contraception', 'Pembrolizumab may have adverse effects on a fetus in utero. Furthermore, it is not known if', 'pembrolizumab has transient adverse effects on the composition of sperm.', 'For this trial, male subjects will be considered to be of non-reproductive potential if they', 'have azoospermia (whether due to having had a vasectomy or due to an underlying medical', 'condition).', 'Chemotherapy can cause fetal harm if administered to pregnant women. Therefore,', 'non-pregnant, non-breastfeeding women may be enrolled if they are considered of', 'non-reproductive potential.', 'Female subjects will be considered of non-reproductive potential if they meet one of the', 'following criteria:', 'She is postmenopausal, defined as at least 12 months with no menses without an', 'alternative medical cause. In women <45 years of age who are not using hormonal', 'contraception or hormonal replacement therapy, a high follicle-stimulating hormone', '(FSH) level in the postmenopausal range may be used to confirm a post-menopausal', 'state. In the absence of 12 months of amenorrhea, a single FSH measurement is', 'insufficient.', 'She had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or', 'bilateral tubal ligation/occlusion at least 6 weeks prior to screening.', 'She has a congenital or an acquired condition that prevents childbearing.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '58', 'Protocol/Amendment No.: 604-09', 'Female and male subjects of reproductive potential must agree to avoid becoming pregnant', 'or impregnating a partner, respectively, while receiving trial drug and for 120 days after the', 'last dose of pembrolizumab and for 180 days after the last dose of chemotherapy by', 'complying with one of the following:', 'Practice abstinence from heterosexual activity.', 'Abstinence (relative to heterosexual activity) can be used as the sole method of', \"contraception if it is consistently employed as the subject's preferred and usual\", 'lifestyle and if considered acceptable by local regulatory agencies and Ethics Review', 'Committees (ERCs)/Institutional Review Boards (IRBs). Periodic abstinence', '(eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are', 'not acceptable methods of contraception.', 'Use (or have their partner use) acceptable contraception during heterosexual activity.', 'Acceptable methods of contraception are$:', 'Single method (one of the following is acceptable):', 'Intrauterine device (IUD)', \"Vasectomy of a female subject's male partner\", 'Contraceptive rod implanted into the skin', 'Combination method (requires use of 2 of the following):', 'Diaphragm with spermicide (cannot be used in conjunction with cervical', 'cap/spermicide)', 'Cervical cap with spermicide (nulliparous women only)', 'Contraceptive sponge (nulliparous women only)', 'Male condom or female condom (cannot be used together)', 'Hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or', 'progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or', 'subcutaneous contraceptive injection', 'IIf a contraceptive method listed above is restricted by local regulations/guidelines, then', 'it', 'does not qualify as an acceptable method of contraception for subjects participating at sites in', 'this country/region.', 'Subjects should be informed that taking the trial medication may involve unknown risks to', 'the fetus (unborn baby) if pregnancy were to occur during the trial. In order to participate in', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '59', 'Protocol/Amendment No.: 604-09', 'the trial, subjects of childbearing potential must adhere to the contraception requirement', '(described above) from the day of trial medication initiation (or 14 days prior to the initiation', 'of trial medication for oral contraception) throughout the trial period up to 120 days after the', 'last dose of pembrolizumab and up to 180 days after last dose of chemotherapeutic agents. If', 'there is any question that a subject of childbearing potential will not reliably comply with the', 'requirements for contraception, that subject should not be entered into the trial.', 'If a female subject inadvertently becomes pregnant while on treatment in this study, the', 'subject will immediately be removed from the study. The site will contact the subject at least', \"monthly and document the subject's status until the pregnancy has been completed or\", 'terminated. The outcome of the pregnancy will be reported to the Sponsor without delay and', 'within 24 hours if the outcome is an SAE (eg, death, abortion, congenital anomaly, or other', 'disabling or life-threatening complication to the mother or newborn). The study investigator', 'will make every effort to obtain permission to follow the outcome of the pregnancy and', 'report the condition of the fetus or newborn to the Sponsor. If a male subject impregnates his', 'female partner, the study personnel at the site must be informed immediately and the', 'pregnancy reported to the Sponsor and followed as described above and in Section 7.2.', '5.7.3 Use in Nursing Women', 'It is unknown whether pembrolizumab is excreted in human milk. As many drugs are', 'excreted in human milk, and because of the potential for serious adverse reactions in the', 'nursing infant, subjects who are breast-feeding are not eligible for enrollment.', '5.8 Subject Withdrawal/Discontinuation Criteria', '5.8.1 Discontinuation of Treatment', 'Discontinuation of trial treatment does not represent withdrawal from the trial.', 'As certain data on clinical events beyond treatment discontinuation may be/are important to', \"the study, they must be collected through the subject's last scheduled follow-up, even if the\", 'subject has discontinued trial treatment. Therefore, all subjects who discontinue trial', 'treatment prior to completion of the treatment period will still continue to participate in the', 'trial as specified in Section 6.0 and Section 7.1.5.7.', 'Subjects may discontinue treatment at any time for any reason or be dropped from trial', 'treatment at the discretion of the investigator should any untoward effect occur. In addition,', 'a subject may be discontinued from trial treatment by the investigator or the Sponsor if', 'treatment is inappropriate, the trial plan is violated, or for administrative and/or other safety', 'reasons. Specific details regarding procedures to be performed at treatment discontinuation', 'are provided in Section 7.1.4 - Other Procedures.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}